Digital Oncology Insights: 27th November- 3rd December 2025

 

  1. MRI-guided cryoablation shows high success in treating renal tumors This study evaluates the efficacy and technical feasibility of using 1.5-Tesla MRI to guide the cryoablation of small renal tumors. Unlike Computed Tomography (CT), MRI guidance offers superior soft-tissue contrast, allowing interventional radiologists to visualize the tumor boundaries more precisely and monitor the "ice ball" formation in real-time without exposing the patient to ionizing radiation. The research demonstrates that closed-bore 1.5 T systems can successfully support these complex interventions using specific imaging sequences like fast spin echo.
    The findings suggest that MRI-guided cryoablation is a safe and effective option for patients who are not candidates for surgical resection. By enabling multi-planar imaging and accurate temperature monitoring during the procedure, this approach ensures complete tumor ablation while sparing healthy renal tissue. This technological validation supports the broader adoption of MRI-guided therapies in interventional oncology.
    Read the original article at: https://pmc.ncbi.nlm.nih.gov/articles/PMC3899798/

  1. MRI outperforms PET for detecting local prostate cancer recurrence A recent comparison of imaging modalities highlights the superior sensitivity of Multiparametric MRI (mpMRI) over PSMA PET-CT for detecting local cancer recurrence following prostatectomy. While PSMA PET-CT is widely recognized for its ability to detect distant metastases, this study reveals that it may miss smaller, localized recurrences in the prostatic bed that MRI successfully identifies. The data indicates only moderate agreement between the two modalities, suggesting they should be viewed as complementary rather than interchangeable.

    These findings have significant implications for post-surgical monitoring protocols. For clinicians suspecting local failure after a prostatectomy, relying solely on PET-CT might lead to false negatives. The study advocates for the continued use of mpMRI as a critical tool for local evaluation, ensuring that patients with localized recurrence can be identified early and considered for salvage therapies.
    Read the original article at: https://www.medscape.com/index/list_12281_0

  1. Standardized pathology reports improve data exchange for cancer care
    Researchers have developed a new method to transform static cancer pathology reports into fully interoperable, computable data. Published in JMIR Medical Informatics, this study details the creation of a standardized electronic reporting format for colorectal cancer using SNOMED CT for clinical terminology and HL7 FHIR (Fast Healthcare Interoperability Resources) for data exchange. The resulting "Structured Data Capture" construct allows complex pathology data to be seamlessly shared between electronic health records and research registries.
    This development addresses a major bottleneck in precision oncology: the trapping of critical diagnostic data in non-computable text or PDF formats. By ensuring that pathology reports are machine-readable and semantically consistent, healthcare systems can better aggregate data for population health management, clinical trial matching, and longitudinal cancer research. The successful implementation demonstrates a scalable pathway for modernizing cancer reporting globally.
    Read the original article at: https://medinform.jmir.org/2025/1/e76870

  1. CRISPR-based gene therapy reduces tumor growth by 50% in models Researchers at UNIST and the Institute for Basic Science have unveiled a novel cancer gene therapy that leverages CRISPR/Cas9 to induce precise single-strand breaks (SSBs) in cancer cell DNA. Unlike traditional methods that create double-strand breaks, this technique simplifies the editing process and significantly lowers the risk of off-target effects. By using just four guide RNAs and incorporating PARP inhibitors—drugs that block DNA repair—the therapy effectively prevents cancer cells from fixing the damage, triggering cell death.
    The study reports a reduction in tumor growth of over 50% in mouse models and demonstrates efficacy in patient-derived organoids. Notably, the inclusion of PARP inhibitors allows this approach to target a broader range of cancers beyond those with specific BRCA mutations. The researchers suggest that this strategy could be combined with radiation therapy to maintain treatment efficacy while reducing debilitating side effects, paving the way for more personalized oncological interventions.
    Read the original article at: https://medicalxpress.com/news/2025-09-gene-technology-enables-destruction-cancer.html

  1. Deep learning and multi-omics drive smarter, personalized oncology treatments
    New developments in artificial intelligence are enabling the integration of multi-omics data to refine precision oncology decision-making. By utilizing deep learning algorithms, researchers can now synthesize vast datasets—combining genomics, transcriptomics, and proteomics—to identify complex biomarker patterns that single-omics approaches often miss. This holistic analysis allows for more accurate predictions of how individual patients will respond to specific cancer therapies.
    The integration of these diverse data layers represents a shift towards truly personalized medicine. Rather than relying on a single genetic mutation to guide treatment, clinicians can leverage these AI-driven insights to understand the tumor's biological landscape comprehensively.
    This approach holds the promise of reducing trial-and-error prescribing and improving clinical outcomes by matching patients with the most effective therapeutic regimens from the outset.

    Read the original article at: https://www.genengnews.com/topics/artificial-intelligence/deep-learning-integrates-multi-omics-for-precision-oncology-decision-making/

  1. Naked mole rat model reveals new insights into lung cancer
    In a significant biological breakthrough, scientists at Moffitt Cancer Center have engineered the first model of lung cancer in naked mole rats, a species famous for its natural cancer resistance. Using CRISPR-Cas9, the team introduced a common oncogene found in human lung cancer but discovered that this alone was insufficient to trigger tumor growth in the animals. Malignancy only occurred when the oncogene was combined with the inactivation of two specific tumor-suppressor genes, p53 and Rb1.

    This finding highlights that cancer development in naked mole rats closely mirrors the multi-step pathogenesis of human cancer, distinguishing it from many mouse models where fewer genetic "hits" are often required. By establishing this unique model, researchers gain a powerful new tool to study the early stages of tumor suppression and resistance. The insights gained from these animals could reveal novel biological mechanisms that may translate into new preventative or therapeutic strategies for human lung cancer.

    Read the original article at: https://medicalxpress.com/news/2025-09-genetically-cancer-naked-mole-rats.html


Follow us on Instagram, Twitter, and Facebook to stay up to date with what's new in healthcare all around the world.

Comments

Post a Comment

Popular posts from this blog

Guesswork gone. A new scoring system (ST-RADS) predicts soft-tissue tumor malignancy with 99.2% accuracy.

Image
 Radiologists may soon have a powerful new standard for evaluating soft-tissue tumors. A study detailed in Radiology Business introduces "ST-RADS" (Soft-Tissue Tumor Reporting and Data System), a structured MRI scoring framework designed to replace the often vague descriptive reports currently in use. In a validation study involving roughly 200 patients, the ST-RADS system demonstrated exceptional precision, achieving a 99.2% accuracy rate in predicting malignancy—significantly outperforming the 92.8% accuracy of standard radiological reports. Crucially, the system was perfect (100% accuracy) in identifying benign tumors, a capability that could drastically reduce unnecessary biopsies and patient anxiety. By standardizing how these complex images are interpreted, ST-RADS offers a clear, objective roadmap for clinicians, ensuring that aggressive cancers are flagged immediately while harmless lumps are safely monitored without invasive intervention. Read the original artic...
Read more

The system is too slow. New data reveals that missed "waiting time" targets are hiding the true, deadly cost of cancer care.

Image
 A critical new analysis argues that current targets for cancer treatment waiting times are failing patients and obscuring the true extent of delays. The report highlights that arbitrary benchmarks such as the 62 day target from referral to treatment are frequently missed and do not account for the increasing complexity of modern cancer care. Patients requiring multiple diagnostic tests often face much longer waits that are not accurately reflected in official data. These delays are not merely administrative nuisances they significantly increase the risk of mortality.  The authors contend that simply setting stricter targets is ineffective without addressing the underlying lack of resources. Instead they call for a national learning system driven by data and collaboration to identify bottlenecks in real time and prioritize patients based on clinical urgency rather than outdated metrics. Read the original article at: http://www.bmj.com/content/392/bmj.s14.short?rss=1 Follow ...
Read more

Digital Oncology Insights: 4th December - 10th December

Image
  1. CTCeptor technology simultaneously isolates tumor cells and fibroblasts for better diagnosis. Diagnosing cancer accurately is often difficult because standard liquid biopsies can miss important cells hiding in the blood. To solve this, researchers at DGIST have developed "CTCeptor," a new technology that captures both circulating tumor cells and the "helper" cells (fibroblasts) that support cancer growth. Most current tests try to filter cells based on their size or specific markers, but they often fail to catch cancer cells that look slightly different. CTCeptor uses a unique extraction method that successfully isolates these cells regardless of their size, providing a much more complete picture of the disease. The impact of this technology on patient care could be profound. In recent trials with breast cancer patients, CTCeptor detected 15 times more tumor cells than existing methods. By analyzing both the cancer cells and their environment, doctors can b...
Read more